Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2831 studies found for:    paclitaxel
Show Display Options
Rank Status Study
1 Recruiting Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel, in Combination With Paclitaxel, or in Combination With Anastrozole
Conditions: Solid Tumors;   Ovarian Cancer;   Endometrial Cancer
Interventions: Drug: ARQ 092 + carboplatin + paclitaxel;   Drug: ARQ 092 + paclitaxel;   Drug: ARQ 092 + anastrozole
2 Active, not recruiting Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Condition: Resectable Pancreatic Adenocarcinoma
Interventions: Drug: LDE-225;   Drug: Gemcitabine;   Drug: nab-paclitaxel
3 Recruiting A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
Condition: Advanced Cancer
Interventions: Drug: AZD2014 3 on/4 off & weekly paclitaxel;   Drug: AZD2014 2 on/5 off & weekly paclitaxel
4 Active, not recruiting BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin;   Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin;   Drug: BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1);   Drug: BKM120, Paclitaxel + Carboplatin
5 Recruiting Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: Enzalutamide;   Drug: Carboplatin;   Drug: Paclitaxel
6 Not yet recruiting Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT
Condition: Malignant Neoplasms of Female Genital Organs
Interventions: Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Emactuzumab
7 Withdrawn A Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: Intraperitoneal tgDCC-E1A;   Drug: Paclitaxel
8 Recruiting Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Conditions: Fallopian Tube Carcinoma;   Recurrent Ovarian Cancer;   Primary Peritoneal Carcinoma;   Recurrent Endometrial Cancer
Interventions: Drug: Lenvatinib Mesylate;   Drug: Paclitaxel;   Other: Pharmacological Study
9 Completed PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: Dasatinib, Paclitaxel, and Carboplatin
10 Active, not recruiting Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Condition: Metastatic Breast Cancer
Interventions: Drug: U3-1287;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Placebo
11 Recruiting Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: nab-paclitaxel IV;   Drug: CC-486;   Drug: Duravalumab
12 Terminated Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: Intraperitoneal tgDCC-E1A;   Drug: Paclitaxel
13 Recruiting Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Condition: Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Trastuzumab;   Drug: Pertuzumab
14 Completed Hepatic Arterial Infusion (HAI) of Abraxane
Conditions: Liver Cancer;   Advanced Cancers;   Solid Tumors
Interventions: Drug: HAI Abraxane;   Procedure: Hepatic Artery Catheter;   Drug: IV Abraxane
15 Active, not recruiting Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
16 Completed Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer
Condition: Advanced Pancreatic Cancer
Interventions: Drug: Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4;   Drug: Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4;   Drug: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4;   Drug: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
17 Completed
Has Results
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Conditions: Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,;   Primary Peritoneal Cancer or Endometrial Cancer;   Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Interventions: Drug: MM-121;   Drug: Paclitaxel
18 Active, not recruiting Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer.
Intervention: Drug: nab-Paclitaxel
19 Completed Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine plus nab-paclitaxel
20 Recruiting Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Pancreatic Neoplasms
Interventions: Drug: nab-Paclitaxel;   Drug: Nivolumab;   Drug: Gemcitabine;   Drug: Carboplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years